Temoporfin

	WikiDoc Resources for Temoporfin
Articles
Most recent articles on Temoporfin Most cited articles on Temoporfin Review articles on Temoporfin Articles on Temoporfin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Temoporfin Images of Temoporfin Photos of Temoporfin Podcasts & MP3s on Temoporfin Videos on Temoporfin
Evidence Based Medicine
Cochrane Collaboration on Temoporfin Bandolier on Temoporfin TRIP on Temoporfin
Clinical Trials
Ongoing Trials on Temoporfin at Clinical Trials.gov Trial results on Temoporfin Clinical Trials on Temoporfin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Temoporfin NICE Guidance on Temoporfin NHS PRODIGY Guidance FDA on Temoporfin CDC on Temoporfin
Books
Books on Temoporfin
News
Temoporfin in the news Be alerted to news on Temoporfin News trends on Temoporfin
Commentary
Blogs on Temoporfin
Definitions
Definitions of Temoporfin
Patient Resources / Community
Patient resources on Temoporfin Discussion groups on Temoporfin Patient Handouts on Temoporfin Directions to Hospitals Treating Temoporfin Risk calculators and risk factors for Temoporfin
Healthcare Provider Resources
Symptoms of Temoporfin Causes & Risk Factors for Temoporfin Diagnostic studies for Temoporfin Treatment of Temoporfin
Continuing Medical Education (CME)
CME Programs on Temoporfin
International
Temoporfin en Espanol Temoporfin en Francais
Business
Temoporfin in the Marketplace Patents on Temoporfin
Experimental / Informatics
List of terms related to Temoporfin

Temoporfin
Clinical data
AHFS/Drugs.com	International Drug Names
[[Regulation of therapeutic goods \|Template:Engvar data]]	EU EMA: by INN;
ATC code	L01XD05 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name 3,3',3'',3'''-(2,3-dihydroporphyrin-5,10,15,20-tetrayl)tetraphenol;
CAS Number	122341-38-2 ;
PubChem CID	60751;
ChemSpider	54754;
UNII	FU21S769PF;
KEGG	D06066 ;
ChEMBL	ChEMBL383675;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C44H32N4O4
Molar mass	680.74 g/mol
3D model (JSmol)	Interactive image;
	SMILES c1cc(cc(c1)O)c2/c3ccc([nH]3)/c(c/4\nc(/c(c\5/cc/c(/[nH]5)c(/c6n\c2\CC6)\c7cccc(c7)O)/c8cccc(c8)O)C=C4)/c9cccc(c9)O;
	InChI InChI=1S/C44H32N4O4/c49-29-9-1-5-25(21-29)41-33-13-15-35(45-33)42(26-6-2-10-30(50)22-26)37-17-19-39(47-37)44(28-8-4-12-32(52)24-28)40-20-18-38(48-40)43(36-16-14-34(41)46-36)27-7-3-11-31(51)23-27/h1-17,19,21-24,46-47,49-52H,18,20H2/b41-33-,41-34-,42-35-,42-37-,43-36-,43-38-,44-39-,44-40-; Key:LYPFDBRUNKHDGX-LWQDQPMZSA-N;
(verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Temoporfin (INN) is a photosensitizer (based on chlorin) used in photodynamic therapy for the treatment of squamous cell carcinoma of the head and neck^[1] .^[2] It is marketed in the European Union under the brand name Foscan. The U.S. Food and Drug Administration (FDA) declined to approve Foscan in 2000. The EU approved its use in June 2001.^[3]

Good results were obtained in 21 of 35 patients treated in Germany.^[4]

It is photoactivated at 652 nm^[5] i.e. by red light.

Patients can remain photosensitive for several weeks after treatment.^[2]

References

↑ Lorenz KJ, Maier H (April 2008). "[Squamous cell carcinoma of the head and neck. Photodynamic therapy with Foscan]". HNO (in German). 56 (4): 402–9. doi:10.1007/s00106-007-1573-1. PMID 17516041.
↑ ^2.0 ^2.1 O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T (2009). "Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy. Photochemistry and Photobiology, Sep/Oct 2009". Photochemistry and Photobiology.
↑ http://www.highbeam.com/doc/1P2-18794532.html Foscan approval saves Scotia's skin.
↑ http://www.springerlink.com/content/g74w224824v8l013/
↑ "Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy". Photochemistry and Photobiology. 2009.

[pmid17516041-1] Lorenz KJ, Maier H (April 2008). "[Squamous cell carcinoma of the head and neck. Photodynamic therapy with Foscan]". HNO (in German). 56 (4): 402–9. doi:10.1007/s00106-007-1573-1. PMID 17516041.

[OGB2009-2] 2.0 ^2.1 O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T (2009). "Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy. Photochemistry and Photobiology, Sep/Oct 2009". Photochemistry and Photobiology.

[3] ttp://www.highbeam.com/doc/1P2-18794532.html Foscan approval saves Scotia's skin.

[4] ttp://www.springerlink.com/content/g74w224824v8l013/

[5] "Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy". Photochemistry and Photobiology. 2009.

[1]

[2]

[3]

[4]

[5]

v t e Chemotherapeutic agents/Antineoplastic agents (L01)
Alkylating and alkylating-like agents	Nitrogen mustards: (Chlorambucil, Chlormethine, Cyclophosphamide, Ifosfamide, Melphalan, Bendamustine, Uramustine) Nitrosoureas:(Carmustine, Fotemustine, Lomustine, Streptozocin) Platinum (alkylating-like): (Carboplatin, Cisplatin, Oxaliplatin, Triplatin tetranitrate, Satraplatin) Alkyl sulfonates:(Busulfan, Treosulfan) Hydrazines:(Procarbazine, Dacarbazine, Temozolomide) Aziridines:(ThioTEPA)
Antimetabolites	Folic acid: (Aminopterin, Methotrexate, Pemetrexed, Raltitrexed). Purine:(Cladribine, Clofarabine, Fludarabine, Mercaptopurine, Pentostatin, Thioguanine) Pyrimidine:(Capecitabine, Cytarabine, Decitabine, Fluorouracil, Floxuridine, Gemcitabine)
Spindle poison/mitotic inhibitor	Taxane: (Docetaxel, Larotaxel, Paclitaxel). Vinca: (Vinblastine, Vincristine, Vindesine, Vinorelbine).
Cytotoxic/antitumor antibiotics	Anthracycline family: (Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, Pixantrone, Valrubicin) streptomyces (Actinomycin, Bleomycin, Mitomycin, Plicamycin) - Hydroxyurea
Topoisomerase inhibitors	Camptotheca: (Camptothecin, Topotecan, Irinotecan, Rubitecan), Podophyllum:(Etoposide, Teniposide)
CI monoclonal antibodies	Receptor tyrosine kinase (Cetuximab, Panitumumab, Trastuzumab) - CD20 (Rituximab, Tositumomab) - other (Alemtuzumab, Bevacizumab, Gemtuzumab)
Photosensitizers	Aminolevulinic acid, Methyl aminolevulinate, Porfimer sodium, Verteporfin
Tyrosine kinase inhibitors	Axitinib, Bosutinib, Cediranib, Dasatinib, Erlotinib, Gefitinib, Imatinib, Lapatinib, Lestaurtinib, Nilotinib, Semaxanib, Sorafenib, Sunitinib, Vandetanib
Cyclin-dependent kinase inhibitor	Seliciclib
Other	retinoids (Alitretinoin, Tretinoin), Fusion protein (Aflibercept) - Altretamine, Amsacrine, Anagrelide, Arsenic trioxide, Asparaginase (Pegaspargase), Bexarotene, Bortezomib, Celecoxib, Denileukin diftitox, Elesclomol, Estramustine, Irofulven, Ixabepilone, Masoprocol, Mitotane, Oblimersen, Testolactone, Tipifarnib, Trabectedin

Temoporfin

Overview

Further reading

References

Navigation menu